Core Viewpoint - The company has entered into a strategic cooperation agreement with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to support the development, industrialization, and commercialization of related products [1][2] Group 1: Strategic Cooperation - The strategic cooperation framework agreement outlines the support the company will provide in research and development, clinical trials, production, registration, and sales promotion [1] - Specific cooperation matters will be detailed in separate agreements between the company and Shengsi Biopharmaceutical [1] Group 2: Market Expansion - The company and its wholly-owned subsidiary aim to enter the recombinant coagulation factor market through this collaboration, aligning with the company's development strategy [2] - The company has obtained exclusive general agency rights for FRSW117 in the Greater China region, which includes mainland China, Hong Kong, Macau, and Taiwan [1]